Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Alkermes plc (ALKS) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, with management scheduled for a fireside chat presentation on June 9, 2025, at 10:00 a.m. EDT.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Alkermes plc (ALKS) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, with management scheduled for a fireside chat presentation on June 9, 2025, at 10:00 a.m. EDT. The presentation will be accessible via webcast on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia, with operations across Ireland, Massachusetts, and Ohio.
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is Alkermes (ALKS) presenting at the Goldman Sachs Healthcare Conference 2025?
Alkermes will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025, at 10:00 a.m. EDT (3:00 p.m. BST).
What products does Alkermes (ALKS) currently have in their portfolio?
Alkermes has commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder.
What areas is Alkermes (ALKS) developing new treatments for?
Alkermes is developing clinical and preclinical candidates for neurological disorders, specifically including narcolepsy and idiopathic hypersomnia.
Where are Alkermes' (ALKS) main operational locations?
Alkermes is headquartered in Ireland, with a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
How long will the webcast of Alkermes' (ALKS) presentation be available?
The webcast will be archived and available for 14 days on Alkermes' website under the Investors tab.
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-46th-annual-goldman-sachs-global-healthcare-conference-302471011.html